Alyeska Investment Group
CNTX icon

Alyeska Investment Group’s Context Therapeutics CNTX Stock Holding History

Alyeska Investment Group’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,663,355
Closed -$2.45M – 633
2025
Q4 		$2.45M Hold
1,663,355
– – 0.01% 512
2025
Q3 		$1.61M Hold
1,663,355
– – ﹤0.01% 518
2025
Q2 		$1.09M Hold
1,663,355
– – ﹤0.01% 503
2025
Q1 		$1.02M Hold
1,663,355
– – ﹤0.01% 437
2024
Q4 		$1.75M Sell
1,663,355
-300
-0% -$519 0.01% 469
2024
Q3 		$3.26M Sell
1,663,655
-271,829
-14% -$603K 0.02% 384
2024
Q2 		$3.85M Buy
+1,935,484
New +$3.34M 0.02% 362

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Alyeska Investment Group's CNTX Position: Q1 2026 in Review

Alyeska Investment Group sold out of Context Therapeutics (CNTX) in Q1 2026, closing a stake of 1,663,355 shares — an estimated $2.45M sold.

Alyeska Investment Group first reported a position in CNTX in Q2 2024 and held it in 7 quarters. The position peaked at $3.85M in Q2 2024. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Alyeska Investment Group reported no remaining Context Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 1,663,355 Context Therapeutics shares in Q1 2026, an estimated $2.45M.
  • Alyeska Investment Group first reported a position in Context Therapeutics in Q2 2024 and held it in 7 quarters.
  • Alyeska Investment Group's Context Therapeutics position peaked at $3.85M in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.